Search results for "Type 2"

showing 10 items of 1034 documents

Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year foll…

2009

Abstract Background and aims Epidemiological prospective data on cardiovascular (CV) events in elderly subjects from Mediterranean populations are lacking. We aimed to investigate 15-year incidence of CV events and to evaluate the association with CV risk factors in an elderly Mediterranean population. Methods and results The population of a small Sicilian village were enrolled, visited and a blood sample was drawn at baseline. CV events were recorded in the 15 years of follow-up. From 1351 subjects (75% of the resident population); 315 were in the age range 65–85 years; 266 subjects free from CV disease were analysed. Seventy-seven CV events were recorded in 73 out of 266 subjects, with a …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEpidemiologyEndocrinology Diabetes and MetabolismPopulationPrevalenceMedicine (miscellaneous)Prospective dataDiseaseDiabetes ComplicationsElderlyRisk FactorsInternal medicineDiabetes mellitusEpidemiologymedicineHumansStatistical analysiseducationAgedAged 80 and overInflammationeducation.field_of_studyNutrition and Dieteticsdiabetesbusiness.industryIncidence (epidemiology)Incidencemedicine.diseaseCardiovascular diseaseLipidsSurvival AnalysisDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHypertensionPhysical therapyFemaleRisk factorCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes.

2005

The lipid triad is the association of small, dense (sd) low-density lipoprotein (LDL), low high-density lipoprotein (HDL), and hypertriglyceridemia, all of which play a role in coronary artery disease in patients with type 2 diabetes. Although statins have demonstrated clear positive effects on cardiovascular morbidity/mortality in patients with diabetes and on single components of the lipid triad, it remains controversial whether they affect all components of the triad in these patients. Therefore, we performed a single-center, parallel-group, prospective, randomized, open-label, blinded-endpoint (PROBE)-type comparison of fluvastatin extended-release (XL) 80 mg (n=48) and simvastatin 20 m…

Malemedicine.medical_specialtySimvastatinIndolesHDLApolipoprotein BSmall dense LDLType 2 diabetesTriglycerideLDLFatty Acids MonounsaturatedFluvastatin XLInternal medicineDiabetes mellitusType 2 diabetes mellitusmedicineHumansPharmacology (medical)Prospective StudiesFluvastatinAgedHypertriglyceridemiabiologybusiness.industryAnticholesteremic AgentsApoA-IHypertriglyceridemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2SimvastatinDelayed-Action Preparationsbiology.proteinlipids (amino acids peptides and proteins)FemaleApoBbusinessLipoproteins HDLFluvastatinmedicine.drugLipoproteinAdvances in therapy
researchProduct

Single-centre, triple-blinded, randomised, 1-year, parallel-group, superiority study to compare the effects of Roux-en-Y gastric bypass and sleeve ga…

2019

IntroductionBariatric surgery is increasingly recognised as an effective treatment option for subjects with type 2 diabetes and obesity; however, there is no conclusive evidence on the superiority of Roux-en-Y gastric bypass or sleeve gastrectomy. The Oseberg study was designed to compare the effects of gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function.Methods and analysisSingle-centre, randomised, triple-blinded, two-armed superiority trial carried out at the Morbid Obesity Centre at Vestfold Hospital Trust in Norway. Eligible patients with type 2 diabetes and obesity were randomly allocated in a 1:1 ratio to either gastric bypass or sleeve gastrecto…

Malemedicine.medical_specialtySleeve gastrectomyβ-cell functionmedicine.medical_treatment1843Gastric BypassBariatric Surgery030209 endocrinology & metabolismType 2 diabeteslaw.invention03 medical and health sciences0302 clinical medicineSuperiority TrialRandomized controlled trialClinical ProtocolslawGastrectomyDiabetes mellitusInternal medicineInsulin-Secreting CellsmedicineProtocolHumans030212 general & internal medicine1506VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771Glycated Hemoglobinbusiness.industryNorwayGeneral Medicinemedicine.diseaseRoux-en-Y anastomosismorbid obesityObesity MorbidDiabetes and EndocrinologyTreatment OutcomeDiabetes Mellitus Type 2GastrectomyFemaleLaparoscopytype 2 diabetesbusinessEpidemiologic MethodsBody mass indexrandomised controlled trialsleeve gastrectomy
researchProduct

Assessment of heart rate variability (HRV) in subjects with type 2 diabetes mellitus with and without diabetic foot: correlations with endothelial dy…

2021

Abstract Background Some studies have suggested that patients with diabetes and foot complications have worse cardiovascular and cerebrovascular risk profiles, higher degrees of endothelial dysfunction and arterial stiffness and a higher inflammatory background than patients with diabetes without diabetic foot complications. Patients with diabetes mellitus have an alteration in the sympathovagal balance as assessed by means of heart rate variability (HRV) analysis, which is also related to the presence of endothelial dysfunction. Other studies suggest a possible role of inflammation coexisting with the alteration in the sympathovagal balance in favor of the atherosclerotic process in a mixe…

Malemedicine.medical_specialtySympathetic Nervous SystemSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismPopulationHyperemia030209 endocrinology & metabolism030204 cardiovascular system & hematologyGPI-Linked Proteins03 medical and health sciences0302 clinical medicineHeart RateLectinsHRV diabetic foot diabetesInternal medicineDiabetes mellitusmedicineDiseases of the circulatory (Cardiovascular) systemHumansOutpatient clinicHeart rate variabilityeducationReactive hyperemiaSerpinsAgedOriginal Investigationeducation.field_of_studybusiness.industryHeartVagus NerveMiddle Agedmedicine.diseaseDiabetic footDiabetic FootCross-Sectional StudiesDiabetes Mellitus Type 2RC666-701Case-Control StudiesArterial stiffnessCardiologyCytokinesFemaleEndothelium VascularSample collectionInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

2018

BackgroundSodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HypothesisWe postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. MethodsNineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30days after initiation of empagliflozin therapy. A mixe…

Malemedicine.medical_specialtyTime FactorsClinical InvestigationsEmpagliflozinRenal functionPilot ProjectsWalk Test030204 cardiovascular system & hematology03 medical and health sciencesExercise Capacity0302 clinical medicineOxygen ConsumptionQuality of lifeGlucosidesInterquartile rangeInternal medicineEmpagliflozinmedicineHumansHypoglycemic Agents030212 general & internal medicineProspective StudiesBenzhydryl CompoundsProspective cohort studyAgedHeart FailureExercise Tolerancebusiness.industryRepeated measures designType 2 Diabetes MellitusGeneral MedicineRecovery of FunctionMiddle AgedEmpagliflozin Exercise Capacity Heart Failuremedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2Heart failureCardiologyQuality of LifeFemaleCardiology and Cardiovascular MedicinebusinessPulmonary Ventilation
researchProduct

Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics an…

2020

Background: Different studies have indicated that thiazide diuretics can increase the risk of developing type 2 diabetes (T2D). Therefore, in this study, we investigated whether switching from hydrochlorothiazide (HCTZ) to amlodipine resulted in ameliorating different cardiovascular and metabolic measures in hypertensive patients with or without T2D. Methods: This study [Diuretics and Diabetes Control (DiaDiC)] was a 6-week, single-blind, single-center randomized controlled trial. The first 20 normal glucose-tolerant, 20 prediabetic, and 20 T2D consecutive patients were randomized to continue the previous antihypertensive treatment with HCTZ (12.5-25 mg/day) or to switch from HCTZ to amlodi…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismSodium Chloride Symporter InhibitorsdiureticBlood PressureType 2 diabetesSettore MED/13 - EndocrinologiaInternal medicineInternal MedicineMedicineHumansSingle-Blind MethodAmlodipineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateThiazideAntihypertensive AgentsAgedtreatmentbusiness.industryDrug Substitutioncardiovascularfood and beveragesMiddle Agedmedicine.diseaseCalcium Channel BlockersDiabetes controlHydrochlorothiazideTreatment OutcomeDiabetes Mellitus Type 2ItalyHypertensionCardiologyFemaletype 2 diabetesAmlodipinethiazidebusinessEnergy MetabolismmetabolismBiomarkersmedicine.drugMetabolic syndrome and related disorders
researchProduct

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2…

2008

To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes.Nine Type 2 diabetic patients (age 61 +/- 10 years, body mass index 30 +/- 5 kg/m(2), glycosylated hemoglobin [HbA1c] 7.5 +/- 0.5%) were randomized in a crossover trial to rosiglitazone 4 mg b.i.d. or pioglitazone 45 mg/day for 12 weeks with an 8-week wash-out period. LDL size and subclasses were determined by non-denaturing polyacrylamide gradient gel electrophoresis. A standardized breakfast was served and variables were assessed after 3 and 6 h.HbA1c, insulin sensitivity (as assessed by the homeostasis model assessment) and…

Malemedicine.medical_specialtyType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)Prospective StudiesTriglyceridesPharmacologyGlycated HemoglobinCross-Over StudiesTriglyceridePioglitazoneCholesterolbusiness.industryGeneral MedicineCholesterol LDLFastingGlucose Tolerance TestMiddle Agedmedicine.diseasePostprandial PeriodLipoproteins LDLPostprandialEndocrinologychemistryDiabetes Mellitus Type 2Low-density lipoproteindense LDL diabetes LDL size pioglitazone postprandial rosiglitazoneElectrophoresis Polyacrylamide GelFemaleThiazolidinedionesbusinessRosiglitazonePioglitazonemedicine.drug
researchProduct

Human leukocyte/endothelial cell interactions and mitochondrial dysfunction in type 2 diabetic patients and their association with silent myocardial …

2013

OBJECTIVE Diabetes is associated with oxidative stress and increased mortality, but a possible correlation between leukocyte-endothelium interactions, oxidative stress, and silent myocardial ischemia (SMI) is yet to be confirmed. RESEARCH DESIGN AND METHODS Mitochondrial dysfunction and interactions between leukocytes and human umbilical vein endothelial cells were evaluated in 200 type 2 diabetic patients (25 with SMI) and 60 body composition– and age-matched control subjects. A possible correlation between these parameters and the onset of SMI was explored, and anthropometric and metabolic parameters were also analyzed. RESULTS Waist, levels of triglycerides, proinflammatory cytokines (i…

Malemedicine.medical_specialtyUmbilical VeinsCardiovascular and Metabolic RiskEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMyocardial IschemiaVascular Cell Adhesion Molecule-1Type 2 diabetesmedicine.disease_causeProinflammatory cytokineInsulin resistanceDiabetes mellitusInternal medicineInternal MedicinemedicineLeukocytesHumansOriginal ResearchAdvanced and Specialized NursingbiologyGlutathione Disulfidebusiness.industryInsulinC-reactive proteinEndothelial CellsMiddle Agedmedicine.diseaseOxidative StressEndocrinologyC-Reactive ProteinDiabetes Mellitus Type 2biology.proteinFemalebusinessReactive Oxygen SpeciesHomeostasisOxidative stress
researchProduct

The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.

2012

Blockade of the renin-angiotensin-aldosterone system (RAAS) affects both the glomerulus and tubules. We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP).A substudy of a double-masked, randomized, cross-over study including 52 patients with type 2 diabetes, hypertension and microalbuminuria. After 2 months washout of all antihypertensive medication except bendroflumethiazid, patients were treated in random order with irbesartan 300, 600 and 900 mg for 2 months.Urinary tubular markers at baseline and after each treatment period (ELISA),…

Malemedicine.medical_specialtyUrinary systemClinical BiochemistryUrologyRenal functionEnzyme-Linked Immunosorbent AssayType 2 diabetesurologic and male genital diseasesFatty Acid-Binding ProteinsDiabetic nephropathyRenin-Angiotensin SystemIrbesartanLipocalin-2Internal medicineDiabetes mellitusProto-Oncogene ProteinsmedicineHumansDiabetic NephropathiesHepatitis A Virus Cellular Receptor 1AgedMembrane Glycoproteinsurogenital systembusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseLipocalinsEndocrinologyKidney TubulesAlbuminuriaReceptors VirusMicroalbuminuriaFemalemedicine.symptombusinessmedicine.drugAcute-Phase ProteinsScandinavian journal of clinical and laboratory investigation
researchProduct

Testosterone Levels in Males with Type 2 Diabetes and Their Relationship with Cardiovascular Risk Factors and Cardiovascular Disease

2010

ABSTRACT Introduction One of the factors involved in type 2 diabetes in males is a reduction in levels of testosterone, which has been shown to predict resistance to insulin and the development of cardiovascular diseases. Aim To assess the levels of testosterone in patients with type 2 diabetes and to evaluate their relationship with cardiovascular risk factors, peripheral arterial disease (PAD) and silent myocardial ischemia (SMI). Methods Total testosterone and sex hormone binding globulin were measured and free and bioavailable testosterones were calculated using Vermeulen's formula. Levels of total testosterone ≥12 nmol/L or free testosterone >225 pmol/L were considered normal. PAD was …

Malemedicine.medical_specialtyUrologyEndocrinology Diabetes and MetabolismMyocardial IschemiaArterial Occlusive DiseasesType 2 diabetesEndocrinologySex hormone-binding globulinInsulin resistanceRisk FactorsDiabetes mellitusInternal medicineHumansMedicineTestosteroneAgedFramingham Risk Scorebiologymedicine.diagnostic_testbusiness.industryTestosterone (patch)Middle Agedmedicine.diseasePsychiatry and Mental healthEndocrinologyDiabetes Mellitus Type 2Reproductive MedicineCardiovascular Diseasesbiology.proteinInsulin ResistanceMetabolic syndromebusinessLipid profileThe Journal of Sexual Medicine
researchProduct